🇺🇸 FDA
Pipeline program

ITF2357

DSC/14/2357/51

Phase 3 small_molecule active

Quick answer

ITF2357 for Duchenne Muscular Dystrophy (DMD) is a Phase 3 program (small_molecule) at Italfarmaco S.p.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Italfarmaco S.p.A.
Indication
Duchenne Muscular Dystrophy (DMD)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials